(ALC) Alcon - Ratings and Ratios

Alcon AG (NYSE:ALC) is a global leader in the eye care industry, specializing in the research, development, manufacturing, and distribution of a comprehensive range of ophthalmic products and technologies. The company operates through two primary segments: Surgical and Vision Care. Its Surgical division offers advanced equipment, instrumentation, and diagnostics, including intraocular lenses (IOLs), implantables, and consumables for cataract and refractive surgery. Key products include the Centurion Vision System, LenSx Laser System, and the NGENUITY 3D Visualization System. The Vision Care segment provides contact lenses, ocular health products, and other solutions for eye care professionals and consumers. Alcons product portfolio also includes vitreoretinal products, such as the Constellation Vision System, and refractive surgery products like WaveLight and Contoura Vision for LASIK procedures. The company is headquartered in Geneva, Switzerland, and has a strong global presence, serving eye care professionals and patients in over 140 countries.

3-month forecast: Based on , Alcons stock is trading near its 20-day SMA of 90.61, with a last price of 92.54, indicating moderate upward momentum. The ATR of 2.59 suggests manageable volatility. From a perspective, the companys high P/E of 45.14 reflects strong growth expectations, while the forward P/E of 27.40 indicates potential valuation compression. The P/S ratio of 4.62 and RoE of 4.72% suggest a balance between revenue generation and profitability. Over the next three months, the stock is likely to find support near the 200-day SMA of 91.21. Upside potential may be driven by improving earnings visibility, while downside risks could stem from broader market volatility or unexpected shifts in demand for ophthalmic products.